Drugs / HZN-1116
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06312020 | May 2024 → Apr 2026 | Sjogren syndrome | Amgen | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HZN-1116 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06312020 ↗ |
| Route | Subcutaneous | “Subcutaneous Administration” NCT06312020 ↗ |